Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Clinical Trials, Phase III as Topic
Dexamethasone
/ administration & dosage
Female
Follow-Up Studies
Humans
Lenalidomide
/ administration & dosage
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Oligopeptides
/ administration & dosage
Prognosis
Randomized Controlled Trials as Topic
Survival Rate
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
05
05
2020
accepted:
29
09
2020
revised:
30
07
2020
pubmed:
18
10
2020
medline:
17
8
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
To understand the profile of best responders (complete response or better [≥CR]) to carfilzomib, we described the characteristics, progression-free survival (PFS), overall survival (OS) data, and the safety of patients who achieved ≥CR to carfilzomib-based treatment in ASPIRE and ENDEAVOR. In post hoc analyses from ASPIRE and ENDEAVOR, median PFS and OS were longer for ≥CR patients versus those who achieved a very good partial response or partial response (VGPR/PR). In the carfilzomib arm of ASPIRE, median PFS was 50.4 months for ≥CR versus 22.1 months for VGPR/PR; median OS was 67.0 versus 44.2 months, respectively. In the carfilzomib arm of ENDEAVOR, median PFS was 34.0 for ≥CR versus 20.4 months for VGPR/PR; median OS was non-estimable. Despite the longer treatment duration, fewer patients with ≥CR versus VGPR/PR experienced treatment-emergent adverse events that led to discontinuation of carfilzomib-based treatment in ASPIRE or ENDEAVOR. Low serum lactate dehydrogenase was the only factor associated with achieving ≥CR vs patients not achieving CR in ASPIRE in multivariate regression analyses. No association was found between cytogenetic risk status and reaching ≥CR. Carfilzomib treatment may lead to rapid and deep responses, irrespective of most patient characteristics.
Identifiants
pubmed: 33067574
doi: 10.1038/s41375-020-01049-5
pii: 10.1038/s41375-020-01049-5
pmc: PMC8179852
doi:
Substances chimiques
Oligopeptides
0
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1732-1744Références
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
pubmed: 25439696
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.
pubmed: 21410373
San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica. 2011;96:1246–8.
pubmed: 21880640
pmcid: 3166092
Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52.
pubmed: 27363832
pmcid: 4929712
Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252–64.
pubmed: 27411022
pmcid: 5096152
Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol. 2017;112:153–70.
pubmed: 28325256
Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252–62.
pubmed: 29257139
European Medicines Agency. Kyprolis® (carfilzomib) summary of product characteristics. 2020. [16 June]; https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf .
United States Food and Drug Administration. Kyprolis® (carfilzomib) prescribing information. 2019. [20 May]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202714s025lbl.pdf .
Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA. An overview of the role of carfilzomib in the treatment of multiple myeloma. Exp Opin Pharmacother. 2017;18:1883–97.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.
pubmed: 25482145
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
pubmed: 26671818
Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, et al. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019;19:522–30 e1.
pubmed: 31160237
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728–34.
pubmed: 29341834
Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018;11:49.
pubmed: 29615082
pmcid: 5883881
Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177:404–13.
pubmed: 28211560
pmcid: 5412871
Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7:e554.
pubmed: 28430175
pmcid: 5436074
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327–37.
pubmed: 28843768
Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hajek R, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115–22.
pubmed: 27491641
Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31:1368–74.
pubmed: 28025582
pmcid: 5467042
van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol. 2017;35:1312–9.
pubmed: 28240968
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30:1005–17.
pubmed: 26710887
Blade J, Rosinol L, Fernandez de Larrea C. How I treat relapsed myeloma. Blood. 2015;125:1532–40.
pubmed: 25587037
Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018;40:480–94.e23.
pubmed: 29500140
Egan P, Drain S, Conway C, Bjourson AJ, Alexander HD. Towards stratified medicine in plasma cell myeloma. Int J Mol Sci. 2016;17:1760.
pmcid: 5085784
Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41:827–35.
pubmed: 26296679
Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117:4696–700.
pubmed: 21292777
pmcid: 3293763
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396–406.
pubmed: 27033237
pmcid: 5004403
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.
pubmed: 26240224
pmcid: 4846284
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–77.
pubmed: 23974982
Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The evolution of prognostic factors in multiple myeloma. Adv Hematol. 2017;2017:4812637.
pubmed: 28321258
pmcid: 5339490
Terpos E, Dimopoulos MA, Kastritis E, Roussou M, Bouwmeester W, Kroep S, et al. External validation of the multiple myeloma (MM) risk-stratification algorithm in a real-world Greek data set. Presented at the 23rd Congress of the European Hematology Association, 14–17 June 2018, Stockholm, Sweden. EHA Learning Center 2018: (abstract PF571).
Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, et al. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol. 2019;187:447–58.
pubmed: 31388996
pmcid: 6899684
Fulciniti M, Munshi NC, Martinez-Lopez J. Deep response in multiple myeloma: a critical review. Biomed Res Int. 2015;2015:832049.
pubmed: 26783530
pmcid: 4689894
Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28:258–68.
pubmed: 23868105
Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114:3139–46.
pubmed: 19638622
Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, et al. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017;102:e313–6.
pubmed: 28522572
pmcid: 5541885
Mangal N, Salem AH, Menon RM, Freise KJ. Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: evaluation of results from 102 clinical trials. Hematol Oncol. 2018;36:547–53.
Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, et al. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed/refractory multiple myeloma in routine clinical care in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:152–60.
pubmed: 29395837
Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33:3459–66.
pubmed: 26282661
San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011;11:38–43.
pubmed: 21273172
Mian HS, Wildes TM, Fiala MA. Development of a medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma. JCO Clin Cancer Inform. 2018;2:1–13.
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128:1174–80.
pubmed: 27439911
pmcid: 5009511
Hájek R, Gonzalez-McQuire S, Szabo Z, Delforge M, DeCosta L, Raab M, et al. A novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma—external validation in a retrospective chart review. BMJ Open. 2020;10:e034209.
pubmed: 32665382
pmcid: 7365483
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.
pubmed: 27511158
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.
pubmed: 16855634